Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron increases number of clinical sites in its PISCES III study

ReNeuron said it had taken the decision to increase the number of sites to ensure that patient recruitment targets in the study are met
Stroke
The PISCES III study is expected to be one of two pivotal studies required to support a marketing authorisation for the therapy

Cell-based therapeutics specialist ReNeuron Group Plc (LON:RENE) is to increase the number of clinical sites in its PISCES III study from 25 to 40.

PISCES III is a phase IIb clinical study in the US of ReNeuron’s CTX cell therapy candidate for stroke disability.

READ: ReNeuron's CTX cells play a part in positive artificial nerve tissue study

ReNeuron said it had taken the decision to increase the number of sites to ensure that patient recruitment targets in the study are met.

First patient dosing in the study is expected in mid-2018 and top-line data from the study, as previously indicated, is expected in late 2019.

The group also updated the market on its hRPC stem cell therapy candidate for retinal diseases and its exosome nanomedicine platform.

hRPC stem cell therapy candidate for retinal diseases

Four cohorts of three patients each have been dosed in the ongoing US phase I/II clinical trial for the blindness-causing inherited retinal disease, retinitis pigmentosa (RP).

ReNeuron said it now expects its hRPC therapy to be most effective in RP patients with sufficiently intact retina to enable good grating of the hRPC cells and subsequent regeneration of functional photoreceptors.

As a result, it is now extending the study to expand the safety database in patients with less impaired vision than those treated thus far.

WATCH: ReNeuron's Michael Hunt updates on product development

This patient group will be targeted in a subsequent clinical trial, which, as previously flagged, will be a controlled phase IIb study.

The expanded phase I/II study will allow ReNeuron to optimise the formulation and dosing of the hRPC therapy ahead of the start of the subsequent study.

Based on the above, ReNeuron expects short-term read-outs from the ongoing phase I/II clinical trial in the first half of 2019, which is later than originally planned, with the phase IIb study commencing shortly thereafter.

Exosome nanomedicine platform

Pre-clinical development work continues with ExoPr0, ReNeuron’s first CTX-derived exosome therapeutic candidate.

Subject to continued success with ongoing pre-clinical development work, ReNeuron hopes to be able to commence clinical development with ExoPr0 during 2019, as previously indicated, targeting a solid tumour cancer indication.

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use